Skip to content
PEPLUX

Synthetic 15-amino-acid peptide

BPC-157 Injection

Also called Body Protection Compound-157.

Illustrative PEPLUX product vial in a purple-lit studio
Product illustration

Product form

Subcutaneous injection

The process

Licensed provider review

BPC-157 Injection cost

$229 per month

*If medically eligible.
Medication
Included
Clinician visit
Included
Baseline labs
Included
Lab retests
Included when ordered by your provider
Shipping
Included
Patient portal access
Included
Care-team chat support
Included

Considering more than one product?

  • Two products prescribed together: $349 per month
  • Three products prescribed together: $479 per month
Compare pricing

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

FDA status, checked on October 13, 2026

BPC-157 Injection is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

Order now

No compounding pathway today. An FDA advisory committee recommendation is not a listing.

*If medically eligible.

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

PEPLUX is a telehealth platform, not a pharmacy or drug manufacturer. Medications are compounded and dispensed by independently licensed US compounding pharmacies.

Prescription products require an online evaluation with a licensed provider. Not all patients qualify.

States served: not yet confirmed. How state availability works

What is BPC-157 Injection?

BPC-157. The salt form (acetate or free base) is not yet documented. The dispensing pharmacy must document it before this product can be ordered.

Adults who want to discuss BPC-157 with a licensed provider after reading its regulatory status, and who accept that any decision to prescribe it rests on animal and laboratory research, not on evidence that it is safe or effective in people.

Key risks

  • Safety in people has not been established. Without controlled human trials, its side effects and longer-term risks are not known.
  • FDA says compounded BPC-157 may pose a risk of immunogenicity (the immune system reacting to the peptide), and that it has identified no, or only limited, safety information for the proposed routes of administration.
All risks and who should not use it

FDA status

FDA status for BPC-157 Injection.

Rendered from our regulatory records, which cite FDA, Federal Register and label documents directly. Each record shows the date we last checked it.

No compounding pathway today. An FDA advisory committee recommendation is not a listing.

BPC-157 Injection is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

An FDA advisory committee recommendation is not a listing. Nothing changes unless FDA publishes a final rule.

BPC-157 Injection

No compounding pathway today. An FDA advisory committee recommendation is not a listing.

FDA’s documents list it as BPC-157.

BPC-157 is not FDA-approved, and there is no pathway for a US pharmacy to compound it today. FDA removed it from its 503A Category 2 in April 2026 after the nominations were withdrawn, but removal is not a listing. FDA's Pharmacy Compounding Advisory Committee recommended it on July 23, 2026. A recommendation is not a listing: nothing changes unless FDA publishes a final rule.

Basis
FDA's 503A categories document of April 15, 2026 announced the removal of BPC-157 from Category 2, effective seven days later, because its nominations were withdrawn. It has no entry in FDA's current 503A or 503B category documents, it is not on the 503A bulks list (21 CFR 216.23) or the 503B bulks list, and it is not a component of an FDA-approved drug. FDA's safety page says compounded BPC-157 may pose a risk of immunogenicity and that FDA has identified no, or only limited, safety-related information for the proposed routes of administration.
Checked on
October 13, 2026

How it works

BPC-157 Injection mechanism.

BPC-157 is a synthetic peptide of 15 amino acids. In laboratory and animal studies, researchers have examined its effects on cell signaling, including signaling involved in the formation of new blood vessels (angiogenesis).

That describes what the molecule does in the body. It is not a claim about what it will do for you.

What the evidence supports

BPC-157 Injection: evidence and limitations.

The research on BPC-157 is mostly in rats and mice, and a large share of it comes from a single research group. Published human data are limited to a few small reports, and no controlled trial has shown that it is safe or effective in people. Results in animals often fail to carry over to people, so the animal findings are not evidence that it works or is safe in people.

Risks

BPC-157 Injection risks and side effects.

  • Safety in people has not been established. Without controlled human trials, its side effects and longer-term risks are not known.
  • FDA says compounded BPC-157 may pose a risk of immunogenicity (the immune system reacting to the peptide), and that it has identified no, or only limited, safety information for the proposed routes of administration.
  • Injection under the skin can cause redness, swelling, pain or bruising at the site, and infection if the injection technique or the product is not sterile.
  • Not for use during pregnancy or breastfeeding, or by anyone under 18, because there is no safety information for these groups. People with an active cancer should not start it without discussing it with their cancer specialist.
  • Stop and seek medical care for signs of an allergic reaction, such as hives, swelling of the face or throat, or difficulty breathing.

This information is educational and is not medical advice. It does not establish a provider–patient relationship.

Clinical review

What your prescriber will consider.

These are decision factors a licensed provider weighs when deciding whether this product is appropriate for you. They are not instructions, and there is no dosing protocol on this page.

  • What you hope to change, how you and the provider would judge it, and whether a better-studied option should come first

  • This listing concerns subcutaneous injection; evidence from another route or formulation cannot be assumed to apply

  • Any personal history of cancer, because animal studies describe effects on blood-vessel growth signaling and this has not been studied for safety in people

  • Every prescription medicine and supplement you take, because interactions have not been studied

  • Whether you are subject to sport drug testing, and how anti-doping rules apply to this substance

PEPLUX does not publish self-administration protocols. Dose, frequency and duration are set by your prescriber against your own history and reviewed over time.

Lot documents

What a certificate of analysis should cover.

When a pharmacy is named, each lot's certificate of analysis is expected to cover the tests below. No certificate exists or is published yet.

  • Potency
  • Sterility
  • Endotoxin
  • pH

Sport and anti-doping

Prohibited under the WADA code.

  • Prohibited at all times under WADA class S0 (non-approved substances).

If you compete under an anti-doping authority, or are tested through your employer or federation, tell your prescriber before you start. Sanctions can follow from possession or purchase records alone, without a positive test.

Straight answers

Common questions about BPC-157 Injection.

What is the FDA status of BPC-157 Injection?
No compounding pathway today. An FDA advisory committee recommendation is not a listing. BPC-157 is not FDA-approved, and there is no pathway for a US pharmacy to compound it today. FDA removed it from its 503A Category 2 in April 2026 after the nominations were withdrawn, but removal is not a listing. FDA's Pharmacy Compounding Advisory Committee recommended it on July 23, 2026. A recommendation is not a listing: nothing changes unless FDA publishes a final rule. Checked against primary sources on October 13, 2026.
Is compounded BPC-157 Injection an approved drug?
No. Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality. BPC-157 Injection is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established. PEPLUX is a telehealth platform, not a pharmacy or drug manufacturer. Medications are compounded and dispensed by independently licensed US compounding pharmacies.
What does the evidence support for BPC-157 Injection, and what does it not?
The research on BPC-157 is mostly in rats and mice, and a large share of it comes from a single research group. Published human data are limited to a few small reports, and no controlled trial has shown that it is safe or effective in people. Results in animals often fail to carry over to people, so the animal findings are not evidence that it works or is safe in people.
What are the risks of BPC-157 Injection?
Safety in people has not been established. Without controlled human trials, its side effects and longer-term risks are not known. The full list of side effects, and of who should not use BPC-157 Injection, is in the risks section of this page. Your prescriber reviews your history before deciding whether it is appropriate for you.
Does BPC-157 Injection require baseline labs?
No. BPC-157 Injection does not require baseline labs, though your prescriber may order them based on your history. Baseline labs are included in the price.
What does BPC-157 Injection cost?
$229 per month. Medication: included. Clinician visit: included. Baseline labs: included. Lab retests: included when ordered by your provider. Shipping: included. Patient portal access: included. Care-team chat support: included. *If medically eligible.
Is BPC-157 Injection prohibited in sport?
Prohibited at all times under WADA class S0 (non-approved substances). If you are subject to anti-doping testing, tell your prescriber before you start. Sanctions can follow from possession or purchase records alone, without a positive test.
How is BPC-157 Injection given?
Subcutaneous injection. Your prescriber decides whether it is appropriate for you and sets the regimen. PEPLUX does not publish dosing.

Next step

A licensed provider reviews every request.

BPC-157 Injection is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

Order now

No compounding pathway today. An FDA advisory committee recommendation is not a listing.

*If medically eligible.

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

Also offered

Other products.

All productsFDA status tracker